Variable | CD30 expression [cases (%)] | P value | |
---|---|---|---|
Positive | Negative | ||
Total | 43 | 48 | Â |
Age (years) | Â | Â | 0.508 |
 ≤60 | 37 (40.6) | 44 (48.4) |  |
 >60 | 6 (6.6) | 4 (4.4) |  |
Sex | Â | Â | 0.675 |
 Male | 33 (36.3) | 35 (38.5) |  |
 Female | 10 (10.9) | 13 (14.3) |  |
B symptoms | Â | Â | 0.627 |
 Yes | 21 (23.1) | 21 (23.1) |  |
 No | 22 (24.1) | 27 (29.7) |  |
Ki-67 index | Â | Â | 0.060 |
 ≤50 | 14 (15.4) | 25 (27.5) |  |
 >50 | 29 (31.8) | 23 (25.3) |  |
Primary site | Â | Â | 0.720 |
 Upper aerodigestive tract | 37 (40.6) | 40 (44.0) |  |
 Others | 6 (6.6) | 8 (8.8) |  |
Ann-Arbor stage | Â | Â | 0.080 |
 I/II | 37 (40.6) | 34 (37.4) |  |
 III/IV | 6 (6.6) | 14 (15.4) |  |
LDH level | Â | Â | 0.894 |
 Elevated | 12 (13.2) | 14 (15.4) |  |
 Normal | 31 (34.0) | 34 (37.4) |  |
Therapeutic modality | Â | Â | 0.230 |
 Chemotherapy alone | 10 (10.9) | 19 (20.9) |  |
 Chemoradiotherapy | 31 (34.0) | 27 (29.7) |  |
 Radiotherapy alone | 1 (1.1) | 1 (1.1) |  |
 Chemotherapy plus surgery | 1 (1.1) | 0 (0.0) |  |
 Unavailable | 0 (0.0) | 1 (1.1) |  |
EBV-DNA status | Â | Â | 0.602 |
 Positive | 19 (20.9) | 20 (22.0) |  |
 Negative | 18 (19.8) | 24 (26.3) |  |
 Unavailable | 6 (6.6) | 4 (4.4) |  |
Relapse | Â | Â | 0.657 |
 Yes | 19 (20.9) | 19 (20.9) |  |
 No | 24 (26.3) | 29 (31.9) |  |